GAY ROBERT C 4
4 · MERRIMACK PHARMACEUTICALS INC · Filed Apr 5, 2012
Insider Transaction Report
Form 4
GAY ROBERT C
Director
Transactions
- Conversion
Common Stock
2012-04-03+175,316→ 175,316 total - Conversion
Series D Convertible Preferred Stock
2012-04-03−142,857→ 0 total(indirect: See footnote)→ Common Stock (142,857 underlying) - Conversion
Common Stock
2012-04-03+142,857→ 318,173 total - Conversion
Common Stock
2012-04-03+175,316→ 493,489 total(indirect: See footnote) - Conversion
Common Stock
2012-04-03+142,857→ 636,346 total(indirect: See footnote) - Conversion
Series B Convertible Preferred Stock
2012-04-03−113,586→ 0 total→ Common Stock (175,316 underlying) - Conversion
Series D Convertible Preferred Stock
2012-04-03−142,857→ 0 total→ Common Stock (142,857 underlying) - Conversion
Series B Convertible Preferred Stock
2012-04-03−113,586→ 0 total(indirect: See footnote)→ Common Stock (175,316 underlying)
Footnotes (3)
- [F1]Each share of Series B Convertible Preferred Stock automatically converted into approximately 1.5435 shares of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.
- [F2]Each share of Series D Convertible Preferred Stock automatically converted into one share of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.
- [F3]These shares are held by the Robert C. Gay 1998 Family Trust, of which Dr. Gay is the grantor. Dr. Gay disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.